Celltrion Views Brazilian Approval As Gateway Into Latin America

Celltrion and its local marketing partner Biomm are working to bring biosimilar trastuzumab to the Brazilian market after receiving approval from local medicines agency Anvisa. A rituximab authorization could soon follow.  

RioDeJaneiro
Celltrion is looking to use its approval for biosimilar trastuzumab in Brazil as a base from whicht to expand in Central and South America • Source: Shutterstock

Celltrion plans to expand its presence in Central and South America after securing approval from Brazil’s Anvisa regulatory agency for its Herzuma (trastuzumab) biosimilar. The South Korean developer is working with its local commercial partner, Biomm, on launch plans for the rival to Roche’s Herceptin.

Herzuma 150mg and 440mg formulations are indicated for metastatic breast and gastric cancer, as well as early-stage breast cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By 

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By 

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

More from Products

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By 

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.